CYTK
Price
$37.23
Change
-$1.66 (-4.27%)
Updated
Jul 18 closing price
Capitalization
4.45B
10 days until earnings call
IDYA
Price
$21.59
Change
-$0.50 (-2.26%)
Updated
Jul 18 closing price
Capitalization
1.89B
23 days until earnings call
Interact to see
Advertisement

CYTK vs IDYA

Header iconCYTK vs IDYA Comparison
Open Charts CYTK vs IDYABanner chart's image
Cytokinetics
Price$37.23
Change-$1.66 (-4.27%)
Volume$1.37M
Capitalization4.45B
IDEAYA Biosciences
Price$21.59
Change-$0.50 (-2.26%)
Volume$549.68K
Capitalization1.89B
CYTK vs IDYA Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. IDYA commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (CYTK: $37.23 vs. IDYA: $21.59)
Brand notoriety: CYTK and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 89% vs. IDYA: 50%
Market capitalization -- CYTK: $4.45B vs. IDYA: $1.89B
CYTK [@Biotechnology] is valued at $4.45B. IDYA’s [@Biotechnology] market capitalization is $1.89B. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 2 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • IDYA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than IDYA.

Price Growth

CYTK (@Biotechnology) experienced а +0.59% price change this week, while IDYA (@Biotechnology) price change was -3.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.45B) has a higher market cap than IDYA($1.89B). IDYA YTD gains are higher at: -15.992 vs. CYTK (-20.855). IDYA has higher annual earnings (EBITDA): -356.46M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. IDYA (693M). IDYA has less debt than CYTK: IDYA (26M) vs CYTK (791M). CYTK has higher revenues than IDYA: CYTK (19.2M) vs IDYA (7M).
CYTKIDYACYTK / IDYA
Capitalization4.45B1.89B235%
EBITDA-513.62M-356.46M144%
Gain YTD-20.855-15.992130%
P/E RatioN/AN/A-
Revenue19.2M7M274%
Total Cash938M693M135%
Total Debt791M26M3,042%
FUNDAMENTALS RATINGS
CYTK vs IDYA: Fundamental Ratings
CYTK
IDYA
OUTLOOK RATING
1..100
2458
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
8380
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
6159
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than CYTK’s over the last 12 months.

IDYA's Profit vs Risk Rating (80) in the null industry is in the same range as CYTK (83) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CYTK’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CYTK’s over the last 12 months.

IDYA's Price Growth Rating (59) in the null industry is in the same range as CYTK (61) in the Biotechnology industry. This means that IDYA’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that CYTK’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKIDYA
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 6 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 12 days ago
77%
Declines
ODDS (%)
Bearish Trend 21 days ago
77%
Bearish Trend 3 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
69%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFOZX19.070.23
+1.22%
Alger Mid Cap Focus Z
SIIIX16.400.03
+0.18%
AlphaCentric Real Income I
VFAIX64.420.09
+0.14%
Vanguard Financials Index Admiral
IEDZX13.720.01
+0.07%
Voya Large Cap Value R6
SDGAX129.57-0.26
-0.20%
DWS Capital Growth A

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IMVT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-4.27%
IMVT - CYTK
53%
Loosely correlated
-2.02%
IDYA - CYTK
49%
Loosely correlated
-2.26%
KRYS - CYTK
47%
Loosely correlated
-1.77%
ROIV - CYTK
46%
Loosely correlated
-1.80%
DNLI - CYTK
44%
Loosely correlated
-3.65%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with CGON. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-2.26%
CGON - IDYA
61%
Loosely correlated
N/A
IMNM - IDYA
61%
Loosely correlated
+1.24%
DNLI - IDYA
60%
Loosely correlated
-3.65%
NRIX - IDYA
59%
Loosely correlated
-7.28%
XENE - IDYA
59%
Loosely correlated
N/A
More